What Is CJC-1295 (No DAC) Used For in Research?
CJC-1295 (No DAC), also known as Modified GRF 1-29, is a synthetic 29-amino acid tetrasubstituted peptide analog of growth hormone-releasing hormone (GHRH). In laboratory settings, researchers evaluate this compound to study receptor-mediated pituitary signaling, pulsatile growth hormone secretion, and downstream insulin-like growth factor 1 (IGF-1) expression.
Quick answer
CJC-1295 (No DAC), also known as Modified GRF 1-29, is a synthetic 29-amino acid tetrasubstituted peptide analog of growth hormone-releasing hormone (GHRH). In laboratory settings, researchers evaluate this compound to study receptor-mediated pituitary signaling, pulsatile growth hormone secretion, and downstream insulin-like growth factor 1 (IGF-1) expression.
Key takeaways
- In preclinical laboratory settings, [CJC-1295 (No DAC)](/product/cjc-1295-no-dac) is primarily used as a targeted secretagogue to investigate physiological growth hormone (GH) release patterns, somatotroph receptor signaling, cellular repair mechanisms, and metabolic substrate partitioning.
- [CJC-1295](/research-peptides/cjc-1295-no-dac) (No DAC) is engineered through four specific amino acid substitutions (Tyr1, Ala2, Asp3, and Asn8 modified to D-Ala2, Gln8, Ala15, and Leu27) relative to native human GHRH(1-29).
- In primary anterior pituitary cell cultures and immortalized somatotroph cell lines, [CJC-1295](/research-peptides/cjc-1295-no-dac) (No DAC) serves as a primary reagent for quantifying intracellular signaling dynamics.
- In vivo rodent models represent a standard experimental platform for examining the systemic effects of [CJC-1295](/research-peptides/cjc-1295-no-dac) (No DAC).
Summary: Primary Research Applications of CJC-1295 (No DAC)
In preclinical laboratory settings, CJC-1295 (No DAC) is primarily used as a targeted secretagogue to investigate physiological growth hormone (GH) release patterns, somatotroph receptor signaling, cellular repair mechanisms, and metabolic substrate partitioning. Because it lacks the Drug Affinity Complex (DAC), the peptide exhibits a half-life of approximately 30 minutes, allowing investigators to mimic natural, physiological GH pulses without causing continuous, non-pulsatile receptor saturation.
Researchers routinely utilize this tetrasubstituted GRF 1-29 derivative to evaluate downstream systemic parameters, including insulin-like growth factor 1 (IGF-1) gene expression, nitrogen retention, collagen synthesis in fibroblast cultures, and musculoskeletal tissue adaptation. Its predictable, short-acting kinetic profile makes it an essential reference standard for comparative studies involving natural GHRH and longer-acting synthetic peptides across our comprehensive catalog of research peptides.
Molecular Structure and Receptor Binding Dynamics
CJC-1295 (No DAC) is engineered through four specific amino acid substitutions (Tyr1, Ala2, Asp3, and Asn8 modified to D-Ala2, Gln8, Ala15, and Leu27) relative to native human GHRH(1-29). These structural modifications enhance enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV) degradation while preserving affinity for the growth hormone-releasing hormone receptor (GHRHR).
Upon binding to GHRHR on anterior pituitary somatotrophs, the compound triggers G-protein coupled receptor (GPCR) activation, leading to elevated intracellular cyclic adenosine monophosphate (cAMP) and activation of protein kinase A (PKA). Preclinical assays demonstrate that this cascade induces exocytosis of pre-stored GH vesicles. Because the peptide is rapidly cleared relative to DAC-bound variants, somatotroph cells return to baseline signaling states, allowing researchers to explore pulse frequency and receptor desensitization kinetics.
In Vitro Research Models: Somatotroph Activation and Cellular Pathways
In primary anterior pituitary cell cultures and immortalized somatotroph cell lines, CJC-1295 (No DAC) serves as a primary reagent for quantifying intracellular signaling dynamics. Investigators measure real-time calcium flux and cAMP accumulation to establish dose-response relationships and receptor activation thresholds. These cellular models demonstrate that the tetrasubstituted analog maintains higher stability in serum-containing media than unmodified native GHRH(1-29).
Additionally, in vitro models involving dermal fibroblasts, osteoblasts, and myoblasts utilize media conditioned with CJC-1295 (No DAC)-induced GH secretions to assess downstream cellular responses. Key endpoints include collagen type I and III gene transcription, cell proliferation rates via MTT assays, and actin cytoskeleton reorganization. These in vitro frameworks provide crucial baseline data before moving into complex animal models documented in the PX1 research library.
Rodent Models and Tissue Repair Endpoints
In vivo rodent models represent a standard experimental platform for examining the systemic effects of CJC-1295 (No DAC). Researchers measure serum GH peak concentration (Cmax) and area under the curve (AUC) post-administration to map short-term endocrine profiles. In these models, repeated physiological GH pulsing leads to sustained elevations in circulating IGF-1 without blunting endogenous pituitary responsiveness.
Tissue regeneration assays in rodent paradigms focus on skeletal muscle hypertrophy, tendon healing, and wound closure. Studies evaluating nitrogen balance demonstrate reduced urinary nitrogen excretion, signaling enhanced amino acid accretion and cellular protein synthesis. Furthermore, histological analysis of transected tendon models frequently reveals accelerated collagen fibril cross-linking and improved biomechanical tensile strength following protocols incorporating GHRH analogs.
Metabolic Substrate Utilization and Adipocyte Signaling
Growth hormone plays a pivotal role in nutrient partitioning and lipid mobilization. In preclinical metabolic research, CJC-1295 (No DAC) is employed to analyze transient shifts in respiratory exchange ratio (RER) and substrate oxidation. Elevated GH levels downstream of receptor stimulation activate hormone-sensitive lipase (HSL) in adipose tissue explants, accelerating the hydrolytic breakdown of stored triglycerides into free fatty acids and glycerol.
Investigators also examine hepatic gene expression patterns associated with gluconeogenesis and glycogenolysis. Preclinical evidence indicates that pulsed GH signaling alters insulin sensitivity pathways differently than continuous GH elevation. By utilizing CJC-1295 (No DAC), metabolic researchers can selectively evaluate the physiological impacts of acute GH spikes on glucose uptake dynamics in skeletal muscle versus visceral adipose tissue.
Synergistic Preclinical Protocols: Dual Secretagogue Mechanisms
A major focus of current neuroendocrine research is the synergistic amplification of GH release achieved by co-administering a GHRH analog alongside a Growth Hormone Secretagogue Receptor (GHSR) agonist. While CJC-1295 (No DAC) acts exclusively via the GHRHR pathway, compounds targeting GHSR (such as Ipamorelin) trigger distinct intracellular pathways mediated by phospholipase C and inositol trisphosphate (IP3).
When evaluated in combination, in vitro and rodent models exhibit a synergistic—rather than additive—surge in total GH release. This experimental design allows investigators to explore how simultaneous activation of cAMP-dependent and IP3-dependent pathways overcomes somatostatin-mediated inhibition, providing insight into complex physiological feedback loops operating within the hypothalamic-pituitary axis.
Comparative Class Analysis: CJC-1295 (No DAC) vs. Related Secretagogues
When designing neuroendocrine trials, investigators must select the secretagogue architecture that best matches their observational goals. Compared to Sermorelin, which features the native GRF 1-29 sequence, CJC-1295 (No DAC) incorporates four amino acid substitutions that extend plasma half-life from several minutes to approximately 30 minutes, drastically reducing enzymatic breakdown by DPP-IV.
Conversely, CJC-1295 DAC includes a maleimide-derived linker that covalently binds to circulating serum albumin, extending its biological half-life to over a week and producing continuous elevation of GH and IGF-1. Meanwhile, Tesamorelin contains a hexenoyl moiety attached to the N-terminus of the full 44-amino acid GHRH sequence, tailored specifically for lipodystrophy models. Researchers favoring physiological, pulsatile release profiles generally select CJC-1295 (No DAC) to avoid long-term pituitary desensitization.
Laboratory Reconstitution and Handling Procedures
Proper reconstitution procedures are critical to maintaining structural integrity and bioactivity of lyophilized CJC-1295 (No DAC). Standard laboratory protocols dictate reconstituting the lyophilized cake using sterile bacteriostatic water containing 0.9% benzyl alcohol. Diluent should be introduced gently along the glass vial wall, avoiding vigorous agitation or mechanical shaking, which can cause peptide aggregation or denaturation.
To calculate precise working concentrations for micro-volume pipetting or Automated Liquid Handling (ALH) systems, researchers should consult the PX1 reconstitution calculator. Reconstituted solutions should be aliquoted under laminar flow to prevent contamination and stored at 2°C to 8°C for short-term assays or -80°C for extended experimental series.
Quality Verification and Manufacturing Standards at PX1 Research
Reliable preclinical outcomes require compounds with verified purity and minimal batch-to-batch variability. PX1 Research manufactures all research peptides in US-based, GMP-compliant facilities adhering to ISO 9001 and ISO 17025 laboratory quality standards. Every production lot undergoes rigorous analytical characterization, including High-Performance Liquid Chromatography (HPLC) to verify chemical purity and Mass Spectrometry (MS) to confirm molecular mass.
Additionally, routinely tested parameters include bacterial endotoxin levels (LAL assay) to ensure suitability for sensitive cell culture and animal models. Researchers can access a lot-specific Certificate of Analysis (COA) directly through our portal. Institutional purchasing departments or laboratory managers managing high-throughput projects can establish dedicated supply arrangements through our wholesale lab program.
Frequently Asked Questions
What is the key functional difference between CJC-1295 with DAC and CJC-1295 No DAC?
CJC-1295 No DAC (Modified GRF 1-29) lacks the Drug Affinity Complex, resulting in a plasma half-life of approximately 30 minutes and inducing discrete, physiological growth hormone pulses. CJC-1295 with DAC covalently binds to serum albumin, extending its half-life to several days and producing continuous, non-pulsatile elevation of GH and IGF-1.
How should CJC-1295 (No DAC) be stored in a laboratory setting?
Lyophilized CJC-1295 (No DAC) should be stored in a freezer at -20°C or -80°C, protected from light and moisture. Following reconstitution with sterile bacteriostatic water, liquid aliquots should be refrigerated between 2°C and 8°C and used within 14 to 28 days to prevent degradation.
What analytical methods are used to verify the purity of CJC-1295 (No DAC)?
PX1 Research verifies CJC-1295 (No DAC) using High-Performance Liquid Chromatography (HPLC) to confirm chromatographic purity (>98%) and Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS) or Electrospray Ionization MS (ESI-MS) to verify exact molecular weight.
Is CJC-1295 (No DAC) suitable for in vitro cell culture research?
Yes. CJC-1295 (No DAC) is frequently utilized in primary pituitary cell assays, somatotroph cell lines, and secondary cell culture models (e.g., osteoblasts, fibroblasts) to evaluate receptor binding, intracellular cAMP generation, and downstream gene transcription.
What endotoxin standards apply to PX1 Research peptides?
All peptide lots undergo Chromogenic Limulus Amebocyte Lysate (LAL) testing to ensure bacterial endotoxin levels remain strictly below published thresholds (<0.1 EU/mg), ensuring compatibility with sensitive in vitro and in vivo models.
Why is CJC-1295 (No DAC) often studied in combination with Ipamorelin?
CJC-1295 (No DAC) targets the GHRH receptor, while Ipamorelin targets the GHSR receptor. In preclinical research, co-administration activates complementary GPCR pathways (cAMP and IP3/DAG), resulting in a synergistic surge of GH release greater than either compound administered alone.
Where can researchers obtain a Certificate of Analysis for their lot?
Lot-specific Certificates of Analysis (COAs) containing HPLC chromatograms, mass spectra, and endotoxin assay results are accessible on the PX1 Research COA portal using the lot number printed on the product vial.
What diluent is recommended for reconstituting CJC-1295 (No DAC)?
Sterile bacteriostatic water (0.9% benzyl alcohol) is recommended for multi-use laboratory applications to prevent microbial growth. For sensitive cell culture protocols sensitive to benzyl alcohol, sterile 0.9% sodium chloride or phosphate-buffered saline (PBS) may be selected for immediate single-use assays.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.